May lamotrigine be an alternative to topiramate in the prevention of migraine with aura? Results of a retrospective study. Issue 2 (24th August 2020)

• Record Type: Journal Article
• Authors: Smeralda, Carmelo Luca; Gigli, Gian Luigi; Janes, Francesco; Valente, Mariarosaria
• Is Part Of: BMJ neurology open. Volume 2:Issue 2(2020)
• Publication Date: 2020-08-24
• Subjects: migraine; Neurology -- Periodicals; 616.8
• DOI: 10.1136/bmjno-2020-000059
• Languages: English
• ISSNs: 2632-6140

Abstract

Abstract : Background: Evidence suggests that lamotrigine could be effective in reducing aura frequency and duration. However, studies comparing lamotrigine to other, first-line prophylactic agents solely involving patients suffering from migraine with aura are still lacking. The aim of this study was to compare the efficacy of lamotrigine and topiramate for the preventive treatment of migraine with aura. Methods: Fifty-three patients suffering from migraine with aura treated with lamotrigine or topiramate for at least 6 months were included. Pre- and post-treatment clinical data regarding monthly aura frequency and duration, monthly migraine frequency, days of headache and rescue medication used per month were collected. Results: Responder rates were similar between the two treatment groups at 6-month follow-up. Interestingly, responder rates for aura frequency and duration were higher in the lamotrigine group compared with the topiramate group (88% vs 79% and 73% vs 54%). Moreover, 50% of the lamotrigine-treated patients reported a complete disappearance of migraine aura compared with 37% of topiramate-treated patients. Side effects were more frequent in topiramate group compared with lamotrigine group (p=0.004). Conclusions: Lamotrigine should be considered in clinical practice for the preventive treatment of migraine with aura especially for patients reporting prolonged aura and who do not respond, have contraindications or discontinue topiramate treatment due to side effects.